acib has identified almost 30 different sepsis-biomarkers based on cell-free or circulating-free DNA (cfDNA) and has chosen the best ones for patient studies with 500+ participants and could show accuracy of >80%. We are now conducting two final blind studies with 100+ participants each in Austria (with the Medical University of Graz) and Germany (with the Charité Berlin). The assay requires a small aliquot of cell-free patient blood and can deliver the test results within 3-4 hours.
acib’s expertise on cfDNA-biomarkers would also allow for detection of other diagnostic tools including bioinformatic predictions for disease severity and risk of death for e.g. SARS-CoV-2, myocardial infection, trauma, transplant graft rejection, cancer,…
acib has ample expertise in providing R&D services to various companies – check also our other offers!